| pubmed-article:17177837 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17177837 | lifeskim:mentions | umls-concept:C0302592 | lld:lifeskim |
| pubmed-article:17177837 | lifeskim:mentions | umls-concept:C0035820 | lld:lifeskim |
| pubmed-article:17177837 | lifeskim:mentions | umls-concept:C0032743 | lld:lifeskim |
| pubmed-article:17177837 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:17177837 | pubmed:dateCreated | 2006-12-20 | lld:pubmed |
| pubmed-article:17177837 | pubmed:abstractText | Cervical cancer patients with histologically documented re-recurrence after curative salvage therapy or unexplained tumor marker elevation (negative computed tomography and/or magnetic resonance imaging [CT-MRI]) proven to be a re-recurrence when a further attempt for cure (or control of cancer) appeared feasible were enrolled. Lesion status was determined from pathology or clinical follow-up for at least 12 months. Management decisions were recorded with CT-MRI alone and incorporating [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET), respectively. The benefits calculated were based on clinical impact because of the FDG-PET findings. Cox proportional hazards model was used to select independent prognostic covariates. Of the 26 patients who were eligible for analysis, 12 (46.2%) patients had positive impacts due to PET. Squamous cell carcinoma (SCC, P = 0.029), re-recurrence at distant metastasis only (P = 0.012), and level of SCC antigen < or = 4 ng/mL (P = 0.005) were significantly associated with better survival. A scoring system using these covariates defined three distinct prognostic groups (P = 0.0001). Patients with score 0 had a 36-month cumulative survival rate of 80%. Using this prognostic scoring system, FDG-PET may facilitate selecting appropriate management for the individual patient with re-recurrent cervical cancer. | lld:pubmed |
| pubmed-article:17177837 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17177837 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17177837 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17177837 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17177837 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17177837 | pubmed:issn | 1048-891X | lld:pubmed |
| pubmed-article:17177837 | pubmed:author | pubmed-author:NguJ LJL | lld:pubmed |
| pubmed-article:17177837 | pubmed:author | pubmed-author:AroJ LJL | lld:pubmed |
| pubmed-article:17177837 | pubmed:author | pubmed-author:IVYR ERE | lld:pubmed |
| pubmed-article:17177837 | pubmed:author | pubmed-author:ChangT-CTC | lld:pubmed |
| pubmed-article:17177837 | pubmed:author | pubmed-author:TsaiC-SCS | lld:pubmed |
| pubmed-article:17177837 | pubmed:author | pubmed-author:QuHuaH | lld:pubmed |
| pubmed-article:17177837 | pubmed:author | pubmed-author:HoK-CKC | lld:pubmed |
| pubmed-article:17177837 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17177837 | pubmed:volume | 16 | lld:pubmed |
| pubmed-article:17177837 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17177837 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17177837 | pubmed:pagination | 1994-2003 | lld:pubmed |
| pubmed-article:17177837 | pubmed:meshHeading | pubmed-meshheading:17177837... | lld:pubmed |
| pubmed-article:17177837 | pubmed:meshHeading | pubmed-meshheading:17177837... | lld:pubmed |
| pubmed-article:17177837 | pubmed:meshHeading | pubmed-meshheading:17177837... | lld:pubmed |
| pubmed-article:17177837 | pubmed:meshHeading | pubmed-meshheading:17177837... | lld:pubmed |
| pubmed-article:17177837 | pubmed:meshHeading | pubmed-meshheading:17177837... | lld:pubmed |
| pubmed-article:17177837 | pubmed:meshHeading | pubmed-meshheading:17177837... | lld:pubmed |
| pubmed-article:17177837 | pubmed:meshHeading | pubmed-meshheading:17177837... | lld:pubmed |
| pubmed-article:17177837 | pubmed:meshHeading | pubmed-meshheading:17177837... | lld:pubmed |
| pubmed-article:17177837 | pubmed:meshHeading | pubmed-meshheading:17177837... | lld:pubmed |
| pubmed-article:17177837 | pubmed:meshHeading | pubmed-meshheading:17177837... | lld:pubmed |
| pubmed-article:17177837 | pubmed:meshHeading | pubmed-meshheading:17177837... | lld:pubmed |
| pubmed-article:17177837 | pubmed:meshHeading | pubmed-meshheading:17177837... | lld:pubmed |
| pubmed-article:17177837 | pubmed:meshHeading | pubmed-meshheading:17177837... | lld:pubmed |
| pubmed-article:17177837 | pubmed:articleTitle | Role of [18F]fluoro-2-deoxy-D-glucose positron emission tomography in re-recurrent cervical cancer. | lld:pubmed |
| pubmed-article:17177837 | pubmed:affiliation | Departments of Obstetrics and Gynecology, Nuclear Medicine, Diagnostic Radiology, and Radiation Oncology, Chang Gung Memorial Hospital, Taoyuan, Taiwan. | lld:pubmed |
| pubmed-article:17177837 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17177837 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
